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Abstract
Background:  Glioblastoma multiforme is the most malignant form of brain tumor. Despite
treatment including surgical resection, adjuvant chemotherapy, and radiation, these tumors
typically recur. The recurrent tumor is often resistant to further therapy with the same agent,
suggesting that the surviving cells that repopulate the tumor mass have an intrinsic genetic
advantage. We previously demonstrated that cells selected for resistance to 1,3-bis(2-chloroethyl)-
1-nitrosourea (BCNU) are near-diploid, with over-representation of part or all of chromosomes 7
and 22. While cells from untreated gliomas often have over-representation of chromosome 7,
chromosome 22 is typically under-represented.
Methods: We have analyzed cells from primary and recurrent tumors from the same patient
before and after in vitro selection for resistance to clinically relevant doses of BCNU. Karyotypic
analyses were done to demonstrate the genetic makeup of these cells, and fluorescent in situ
hybridization analyses have defined the region(s) of chromosome 22 retained in these BCNU-
resistant cells.
Results: Karyotypic analyses demonstrated that cells selected for BCNU resistance were near-
diploid with over-representation of chromosomes 7 and 22. In cells where whole copies of
chromosome 22 were not identified, numerous fragments of this chromosome were retained and
inserted into several marker and derivative chromosomes. Fluorescent in situ hybridization analyses
using whole chromosome paints confirmed this finding. Additional FISH analysis using bacterial
artificial chromosome probes spanning the length of chromosome 22 have allowed us to map the
over-represented region to 22q12.3–13.32.
Conclusion: Cells selected for BCNU resistance either in vivo or in vitro retain sequences mapped
to chromosome 22. The specific over-representation of sequences mapped to 22q12.3–13.32
suggest the presence of a DNA sequence important to BCNU survival and/or resistance located in
this region of chromosome 22.
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Background
Treatment of human malignant gliomas often includes
surgical resection followed by chemotherapy and radia-
tion; however, it is common for such tumors to recur
despite adjuvant therapy [1]. The recurrent tumor is often
resistant to further therapy with the same agent, suggest-
ing that cells which survive treatment and repopulate the
tumor mass have an intrinsic genetic advantage. We have
previously demonstrated that cells selected for resistance
to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in vitro
or in vivo (recurrent tumor) were near diploid, with over-
representation of part or all of chromosomes 7 and 22 [2].
Whereas over-representation of chromosome 7 is com-
mon in gliomas, chromosome 22 is not typically over-rep-
resented, and in fact it is often under-represented in
untreated gliomas [3-7]. However, when a sufficient
number of karyotypes are done it is possible to identify
cells with over-representation of chromosome 22 in
untreated tumors. These cells represent a very minor pro-
portion of the cells in the primary, untreated tumor, but
become a major subpopulation after treatment. We were
able to demonstrate that this is likely due to selection of
these cells through the identification of karyotypic mark-
ers in cells from the primary and recurrent tumors [2].
Thus, selection for cells with over-representation of chro-
mosome 22 sequences by BCNU treatment suggests the
presence on this chromosome of a gene or genes that con-
fer a selective advantage to these cells.
We originally analyzed the expression of platelet-derived
growth factor because the genes encoding the A and B
chains of this growth factor are mapped to chromosome
regions 7p22 and 22q13.1, respectively. Whereas we dem-
onstrated increased expression of these genes in some
BCNU-resistant cells, it was likely that this over-expres-
sion provided a growth advantage and was not directly
involved in resistance [8]. We also analyzed the expres-
sion of glutathione-S-transferase theta 1, a gene mapped
to 22q11.23. Over-expression of this gene at the RNA level
was not found in the majority of our BCNU resistant cells
[9].
The specific over-representation of chromosome 22
sequences provides strong evidence that a gene(s) on this
chromosome is important for survival after therapy and/
or therapy resistance. The availability of samples from
tumors that recurred following therapy with BCNU and
radiation provided us with a unique opportunity to exam-
ine cells that survived therapy in vivo. To assist in the iden-
tification of the gene(s) involved in the growth of BCNU
resistant cells, we established sets of 4 cell lines from each
of three patients (Table 1); cells from the primary tumor,
cells from the primary tumor selected for resistance to 10
µg/ml of BCNU in vitro, cells from recurrent tumor (in vivo
selection), and cells from recurrent tumor selected for
resistance to 10 µg/ml of BCNU. These cells were analyzed
for the retention of chromosome 22 by karyotypic analy-
ses and the specific regions that were retained were identi-
fied using fluorescent in situ hybridization with bacterial
artificial chromosome (BAC) probes.
Methods
Cell culture and selection for drug resistant cell 
populations
The availability of samples from tumors that recurred after
therapy provided us with a unique opportunity to exam-
ine cells that survived therapy in vivo. Patients from whom
we have cell lines derived from both primary and recur-
rent tumor samples were used for this study (Table 1). The
time between surgeries and overall survival for patients
this age was not unusual. All three patients received gross
total resections of their primary tumor and all were then
treated with BCNU and radiation. All three showed
increased enhancement within 3 months of the primary
surgery, demonstrating rapid progression of the tumors.
Table 1: Patient information
Tumor codea Ageb Sex Diagnosisc Treatmentd Days between primary 
and secondary surgery
Survival (days)
DI/DIR 38 F GBM Irradiation and BCNU 111 426
LX/LXR 48 M Gliosarc./GBMe Irradiation and BCNU 203 466
ME/MER 49 F GBM Irradiation and BCNU 138 285
a The tumor code is a random 2 letter code. Recurrent tumor from the same patient receives the same code with the addition of R. For each 
patient the primary and recurrent tumors were diagnosed by the same neuropathologist.
b Age in years at diagnosis of primary tumor.
c GBM = glioblastoma multiforme; gliosarc. = gliosarcoma.
d BCNU = 1,3-bis(2-chloroethyl)-1-nitrosourea.
e Different diagnoses of primary and recurrent tumors. Gliosarcoma is considered a variant of glioblastoma multiforme and the gliomatous and 
sarcomatous areas have similar genetic profiles and are thought to have a monoclonal origin [22,23]. Tumor LX was primarily glial, with a small 
sarcomatous element.BMC Cancer 2006, 6:2 http://www.biomedcentral.com/1471-2407/6/2
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Within a year all three required surgery for recurrent
tumor (Table 1).
Primary tumors were given a random 2-letter code desig-
nation, and the recurrent tumor from the same patient
received the same code with the addition of "R" (ME/
MER, LX/LXR, DI/DIR). Cell lines were derived as
described [10,11] and grown in Waymouth MAB 87/3
medium (MAB) with 20% fetal calf serum (FCS). The pas-
sage number of the cells used for all experiments varied
(LX/LXR 15–32, DI 5–25, DIR 15–40, ME 18–41; MER
52–120); however, the results of repeats done at different
passage numbers were consistent. Cells were selected for
resistance to 10 µg/ml BCNU as described [10,12], and
mock treatment of the cells was done in parallel. Briefly,
cells were washed with MAB without serum 3 times; they
were then mock-treated using MAB without serum or
drug, or treated with BCNU in MAB without serum for 1
hour at 37°C with 5% CO2. Cells were washed and fed
with MAB containing 20% serum. The cells were treated
with the same concentration of BCNU for three consecu-
tive days, after which the cells were allowed to grow. This
step was repeated several times until the resulting cell
population was resistant, as evidenced by the absence of
cytopathic effect and cell debris in the media which would
indicate cell death after treatment when compared to the
mock-treated controls. When cells appeared resistant to a
particular dose of BCNU, subsequent treatment was done
at a higher dose (2.5, 5.0, 7.5, 10.0 µg/ml) until cells were
resistant to 10 µg/ml. The time required to select for a
resistant cell population varied for the different cell lines.
For example, DI cells required approximately 3 months to
get a cell line fully resistant to 10 µg/ml BCNU. Tumor cell
lines LX and ME required 4–6 months. Selection for resist-
ant cells from recurrent tumors (DIR, LXR, MER) was
complete in 2–3 months for all cell lines, reflecting the
higher level of intrinsic resistance in cells from the recur-
rent tumors compared to cells from the primary tumor.
Karyotypes Figure 2
Karyotypes. (A) Representative karyotype from the pri-
mary LX tumor cell passage 2. Karyotypic deviation: 57XX, 
+2, i(6)(p10), +7, +7, +8, +9, 
der(9)t(9;12)(p13;q11)ins(9;?)(p13;?), +11, +11, +12, +14, 
+15, +16, -17, del(17)(p11.2), +21, -22, + mar. (B) Repre-
sentative karyotype from the recurrent LXR tumor cell pas-
sage 3. Karyotypic deviation: 49XX, del(1)(q12), 
+der(2)t(2;9)(p13;q13), der(3)ins(3;?)(p23;?), add(3)(q21), 
der(4)t(4;8)(q13.2;q11.2), -5, add(5)(q11.1), -6, 
der(6)t(1;6)(p11;q11), +add(7)(q21.2), -9, add(9)(q32), -10, 
add(11)(p11.2), -12, add(12)(q24.3), -13, add(15)(q21.2), -16, 
del(17)(p11.2) ×2, +add(20)(q11.1), -21, +22, +22, +5 mar.
Chromosome 22 ideogram Figure 1
Chromosome 22 ideogram. Chromosome 22 ideogram 
showing the size and location of the individual BACs and the 
4 grouped BAC pools used in this study. a bp position 
obtained from The Sanger Center; b set denotes BAC pools.BMC Cancer 2006, 6:2 http://www.biomedcentral.com/1471-2407/6/2
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Cells were re-treated with 10 µg/ml BCNU every 8–10 pas-
sages to maintain the resistant phenotype.
Karyotype analysis
Karyotype analysis was done on low passage cells as
described previously [13]. Briefly, mitotic cells from
mock-treated or BCNU-resistant cultures were harvested
by banging the sides of the flasks to release dividing cells
into the medium. Cells were pelleted, swelled using 0.075
M KCl at 37°C for 17 min and 22 sec, and fixed with
methanol/acetic acid (3:1). Cells were then dropped onto
slides, rinsed with methanol/acetic acid, dried, and stored
until use [14]. The nomenclature follows ISCN recom-
mendations [15,16]. Chromosomal abnormalities were
classified as clonal if two or more metaphases had an
identical structural abnormality, or five or more met-
aphases had gained or lost a specific chromosome. Non-
clonal cells represent cells in which unique structural
arrangements, telomeric fusions, somatic exchanges and/
or different states of chromosome contraction occur.
Probes for FISH analyses
Whole chromosome paint for chromosome 22 (Vysis,
Inc., Downers Grove, IL) was used following conditions
specified by the manufacturer. Bacterial artificial chromo-
somes (BACs) spanning the q arm of chromosome 22 at
2-megabase intervals (2 Mb BAC Set; a kind gift from The
Sanger Institute, Cambridge, UK) were used to identify the
regions of chromosome 22 retained in BCNU resistant
cells (Figure 1). The BACs were grown and purified
according to standard protocols [17]. To verify that there
was no cross hybridization to other chromosomes, BACs
were tested against CGH Metaphase Target Slides which
contain metaphases derived from karyotypically normal
male cultured lymphocytes (Vysis Inc.). Labeling with
SpectrumGreen™ or SpectrumOrange™ was done with a
Nick Translation kit (Vysis) under conditions specified by
the manufacturer. For identifying the region of chromo-
some 22 retained in BCNU-resistant cells, BAC DNAs
were individually labeled and tested prior to being sepa-
rated into one of 4 groups (Figure 1). Pooled probes con-
tained 0.1 µg of each BAC DNA, 5 µg salmon sperm DNA,
and 6 µg Cot-I DNA. Individual BAC probes contained 0.1
µg of BAC DNA, 5 µg salmon sperm DNA, and 1 µg Cot-I
DNA.
To verify the hybridization efficiency of our probes the
BACs were separated into 2 groups (Pools A+B and C+D)
and tested using CGH Metaphase Target Slides (Vysis).
Ninety five percent (102/107 cells counted) of the met-
aphase spreads were diploid when pool A+B was used as
probe and 94% (113/120) were diploid using C+D.
Cell preparation and FISH analysis
Mitotic cells from mock-treated or BCNU-resistant cul-
tures were harvested by banging the sides of the flasks to
Table 2: Karyotype analysis of primary/recurrent tumor cells
Clonal Designation Karyotypic deviation
DI 45,X,-X,+7,-10[9]/45,idem,-9,der(9)t(9;11)(p22;q21),-11[13]/45,idem,-9,der(9)t(9;11)(p22;q21),-11,-14,-18,del(11) 
(q21),der(14)t(14;18)(P11;q12),der(22)t(22:?)(p11;?)[44]/90,idem ×2[5]/88,idem ×2,+6,+11,-11,+15,15,+19 [cp12]/85-
86,idem,+X,-3,+5,-8,+11,-11,+12,+12,-13,+15,-15,i(15q),-19,+20,-20,+21[31]
non-clonal cells [1]
46,XX[13]
DIR 45,X,-X,+7,-9,-10,-11,-14,-18,der(9)t(9;11)(p22;q21),del(11)(q21),der(14)t(14;18)(P11;q12),der(22)t(22:?) (p11;?)[159]
non-clonal cells[7]
ME 45,XX,del(9)(p13),add(9)(p21),+9-13,-17[9]/47,idem,+mar1,+mar2,1-3dmin[6]/48,idem,+7[8]/49,idem,+mar3[13]/
90,idem×2[5]/80-85,idem×2,-1,+8,-8,-10,+11,-11,+12,-12,-19,-21,-21-22,+mar3,3-7dmin[cp38]
non-clonal cells [9]
46,XX[6]
MER 55,X,der(X)t(X:?)(q25;?),der(1)t(1;?)((p32;?),×2,+1,inv(2)(p13q21),der(2)t(2;14)(q23;q13),add(2)(p25.1),+2,add(3) (q29) 
×2,+3,-4,del(5)(q13),-5,iso(7)(p11.1),der(9)t(9;1)(p22;p13),del(10)(p11.2), der(10)t(10;?)(q22;?),inv(11)(q13q23)×2,+11,-
12,-13,-15, -17,add(18)(q23),add(19)(q13.3), add(20)(q13.3),-22,+mar1,+mar2,+mar3,+mar4,+mar5[16]/56,idem, +7,[36]/
57,+7,+mar6 [5]
non-clonal cells [23]
LX 56-57,XX,+1,-1,+2,+2,+6,-6,i(6)(p10),+7,+7,+8,+9,der(9)t(9;12)(p13;q11),ins(9;?)(p13;?),+11,+14,+15,+16,-
17,del(17)(p11.2),+21,-22,2-3mar[cp11]69,XX,+1,+3, add(3) 
(q29),x2,+3,+3,+4,del(5)(p13.3p15.1)del(6)q22)×2,+6,+7,+7,+7,del(9)(p13) ×2,+11,+11,+12,+15, +15,-17,-17,+18, 
+18,+20,+20,+21,+21,+mar3,+mar4,+mar5,[21]/68,idem,-10,-mar3,+mar5[19]/67,idem,-3, -10,+17,-mar3,+mar6[10]
non-clonal cells [6]
LXR 46-49,XX, +1, -1, del(1)(p13), del(1)(q12), del(1)(q25), der(?)t(1;?)(q21;?),-2, -2, 
der(2)t(2;9)(p13;q13),der(2)ins(2;4)(q11.2;12q34), add(2)(q31), -3, add(3)(q21), del(3)(p22;p23),-4, 
der(4)t(4;8)(q13.2;q11.2), -5, del(5)(p15.1;p15.2), add(5)(q11.1), -6, der(6)t(1;6)(p11;q11), del(6)(q21), add(7)(q21.2), 
+der(7)t(7;?)(q11.2;?), -9, add(9)(q32), -10, +11, add(11)(p11.2), -12, add(12)(q24.3), -13, add(15)(q21.2), -16, 
del(17)(p11.2) ×2, add(20)(q11.1), -21, +22, 5, -6, mar[cp41]
non-clonal (16)BMC Cancer 2006, 6:2 http://www.biomedcentral.com/1471-2407/6/2
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release dividing cells into the medium. Cells were pel-
leted, swelled using 0.075 M KCl at 37°C for 17 min and
22 sec, and fixed with methanol/acetic acid (3:1). Cells
were then dropped onto slides, rinsed with methanol/ace-
tic acid, dried, and stored until use [14]. Slides used for
FISH were denatured in 70% deionized formamide at
73°C for 5 min, dehydrated, and hybridized with 10 µl
hybridization mix consisting of labeled BAC probes in LSI
hybridization buffer (Vysis) at 37°C for approximately 20
hours in a Perkin Elmer GeneAmp System 1000 in situ
hybridization instrument. Slides were then washed in 0.4
× SSC (Vysis) for 2 min at 73°C, rinsed with 2 × SSC at
room temperature, and left to air-dry. Preparations were
counterstained with propiduim iodide or DAPI, and FISH
signals were visualized and captured with a Zeiss Pascal 5
Laser Scanning Confocal Microscope. At least 75 met-
aphase cells per cell line were examined; chromosome
fragments were considered over-represented if three or
more copies were seen per cell. Statistical analysis was
done using the SAS (Statistical Analysis Software, SAS
Institute, Inc, Cary, NC) PROC logistic regression method.
Results
Karyotype analysis
Figure 2A and 2B show representative karyotypes from the
primary (A) and recurrent (B) tumors from patient coded
LX/LXR and Table 2 gives a summary of the results for all
three patients. Karyotype analysis was done on low pas-
sage cells to avoid artifacts that could arise from long term
in vitro cultivation. Primary (passage 0) cells from tumors
DI, DIR, ME and LX were prepared and analyzed as
described in the Material and Methods. Cells from MER
and LXR were analyzed following one serial passage. Pri-
mary untreated tumors generally contained 2 or more
non-related stem line populations which frequently dif-
fered in the gain and/or loss of whole chromosomes in
addition to different clonal markers. In contrast, recurrent
tumor samples obtained within a year or less of the pri-
mary surgery generally had only a single stem line in the
samples we could analyze. The recurrent tumor stem lines
also contain very complex karyotypes with multiple
abnormalities including non-reciprocal translocations,
deletions, duplications and marker chromosomes. Whole
chromosomes 7 and/or 22 were over-represented in
tumors DI and DIR [10]. In tumors ME and MER we were
able to identify at least 2 normal and/or derivative chro-
mosome 7 and 22's in addition to 1–5 marker chromo-
somes. Chromosome 7 was over-represented in the
primary tumor LX while in recurrent tumor LXR only one
normal chromosome 7 was present along with 1–3 deriv-
ative 7 s. Chromosome 22 was under-represented in the
primary and over-represented in the recurrent tumor in
addition to fragments within some of the derivative chro-
mosomes and marker chromosomes.
FISH analyses
To identify the regions of chromosome 22 that were
retained in the chromosome 22 fragments in cells from
recurrent tumor and cells selected for BCNU resistance in
vitro we used fluorescent in situ hybridization (FISH). We
FISH using whole chromosome paint for chromosome 22 Figure 3
FISH using whole chromosome paint for chromo-
some 22. Whole chromosome paint for chromosome 22 
labeled with SpectrumOrange™, showing the presence of 
chromosome 22 fragments in (A) cell line ME and (B) cell line 
MER.BMC Cancer 2006, 6:2 http://www.biomedcentral.com/1471-2407/6/2
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Over-representation of BAC probes in the ME/MER cell line series Figure 4
Over-representation of BAC probes in the ME/MER cell line series. (A) FISH using BAC pool D as probe on cell line 
MER. Arrows indicate BAC sequences. (B) Graphs showing over-representation of pooled BAC probes in the ME/MER cell line 
series.BMC Cancer 2006, 6:2 http://www.biomedcentral.com/1471-2407/6/2
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began by confirming previous karyotypic results demon-
strating over-representation of part or all of chromosome
22 in cells selected for resistance in vitro or in vivo (recur-
rent tumor) using whole chromosome paint (WCP) for
chromosome 22. There was an increase in the number of
fluorescent signals from chromosome 22 in cells selected
for resistance to BCNU in vitro or in vivo when compared
to cells from primary, untreated tumor. Fragments of
chromosome 22 were particularly evident in cells from
recurrent tumor MER (Figure 3).
To identify the region of chromosome 22 that is over-rep-
resented in BCNU resistant cells, we began with pooled
BAC probes (Figure 1). Whereas over-representation of
BAC DNA sequences from all four regions could be found
in some cells such as MER, over-representation of
sequences from BAC pools C and D was particularly evi-
dent in cells from all recurrent tumors, with an increase
seen when these cells were further selected in vitro for
BCNU resistance as shown in Figure 4 for tumors ME/
MER. In this figure, the black bars representing BAC pool
D can be seen to shift to higher signal numbers when the
cells are selected for BCNU resistance. In fact, when cells
from recurrent tumor were selected for resistance to
BCNU, the region most commonly over-represented cor-
responded to BACs in the C and D groups (Figure 4).
Logistic Regression was used to compare the portion of
each of the signals in each group (A, B, C, D) of chromo-
some 22. Analyses were then done to demonstrate statis-
tical significance of the results of group A & B compared
with C & D. PROC logistic regression was used to analyze
ME mock versus ME drug and MER mock versus MER
drug. The shift of signals from BAC clone groups C & D in
ME mock versus MER mock was statistically significant
(<.0001). These was also a statistically significant differ-
ence between BAC groups A & B versus C & D when ME
mock is compared to ME drug (.0122). Finally, the shift in
signal number between MER mock and MER Drug was
also statistically significant (<.0001).
To further map the region(s) of chromosome 22 retained
in cells from recurrent tumor and in cells from recurrent
tumor selected for resistance to BCNU, we used individual
BACs as FISH probes (Table 3 and Figure 5). This work
demonstrated that the region retained most frequently is
between BACs bk212A2 and bk299D3, which corre-
sponds to 22q12.3–13.32. BACs outside of this region did
not show frequent retention in these cells. Differences in
the specific pattern of BAC representation in each cell line
(Figure 5) provides evidence that the observed similarities
are not due to cross-contamination of the cell lines.
Discussion
Genetic analyses of primary human malignant gliomas
have demonstrated numerous alterations including the
over-representation of chromosome 7, and normal or
under-representation of chromosome 22 in primary
untreated glioblastomas multiforme [18]. Molecular
Table 3: Retained BAC DNAs in cells from recurrent tumor selected for resistance to 10 µg/ml BCNU.
Cell Line # of 
signals
221H1 212A2 390B3 150C2 229A8 250D10 397C4 268H5 1109B5 299D3
D I R 0797 1 0 333236
1 9 15 19 15 41 55 3 4 9 11
2 2 53 94 13 72 92 61 82 51 93 4
3 3 53 12 42 92 11 34 03 23 84 6
4 18 10 8 5 4 14 19 16 3
L X R 07283000000
15564000000
2 1 0 7 1 2 3000000
3 2 52 63 33 23 92 62 94 13 22 4
41 8 1 151 153 19 81 2 1 1
5 20 15 9 15 16 19 28 35 17 38
6 2 43 63 12 52 81 5 9 1 42 71 4
76549 2 1 2 4 1 8 1 2 1 2 1 5
82002237320
M E R 00002124252
17 1 5 3 1 1 279794
2 3 64 13 03 92 51 91 0 8 1 41 3
3 4 82 04 62 12 93 43 94 24 75 9
4 2 92 42 22 64 13 13 74 53 33 9
5 5 13 7 6 5 10 10 17 12 6
635 1 7 3976285
70041395422
80010162342BMC Cancer 2006, 6:2 http://www.biomedcentral.com/1471-2407/6/2
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cytogenetic analyses echoed the heterogeneity and com-
plex genetics of these tumors identified by standard
cytogenetics. The majority of malignant gliomas recur at
or near the site of the original tumor, and it is thought that
recurrent tumor arises from cells that survived the
patient's treatment. Thus, cells in the recurrent tumor can
be thought of as being selected for resistance in vivo. This
is further suggested by cells in the recurrent tumor that
carry markers identified in the primary untreated cells, i.e.
del(17)(p11.2) found in the LX and LXR cells shown in
Figure 2. We have demonstrated that the heterogeneity
present in primary tumors is markedly reduced in recur-
rent tumors suggesting that among the large number of
genetic subpopulations, several may contain resistance
and/or survival factors that permit selection and propaga-
tion. However, despite the presence of complex karyo-
types with multiple abnormalities, cells selected for
BCNU resistance in vitro or in vivo have a specific genetic
characteristic – near diploid with over-representation of
chromosome 7 and part, or all of chromosome 22 [2,10].
While in recurrent tumors whole copies of chromosome
22 may be under-represented, FISH analysis demon-
strated that numerous fragments of chromosome 22 were
inserted in derivative and marker chromosomes. This was
not found for other chromosomes when analyzed in a
similar manner, and additional fragments of all other
Copy number of BACs in cells from recurrent tumors resistant to 10 µg/ml BCNU Figure 5
Copy number of BACs in cells from recurrent tumors resistant to 10 µg/ml BCNU. Tumor DIR did not have more 
than 4 signals for any BAC probe.BMC Cancer 2006, 6:2 http://www.biomedcentral.com/1471-2407/6/2
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chromosomes were only randomly retained. To map the
region of chromosome 22 that is over-represented in
BCNU-resistant cells, we performed FISH analyses using
pooled BAC probes. The over-represented region was fur-
ther defined by use of individual BACs. This work estab-
lished that this region encompassed 22q12.3–13.32.
When cells from recurrent tumor were further selected in
vitro for BCNU resistance, the percentage of cells contain-
ing the retained region of chromosome 22 increased, sug-
gesting a role in BCNU resistance and/or cell survival for
a gene or genes mapped to this region. One gene mapped
to this region is the gene encoding the B-chain of platelet-
derived growth factor (PDGF-B) [19]. We have previously
demonstrated that this gene is over-expressed in cells
selected for resistance to BCNU and is probably involved
in the autocrine growth of these cells [10]; however, there
is no evidence that expression of this gene is directly
involved in chemotherapy resistance. Differential mRNA
display and cDNA microarray analyses have not demon-
strated consistent over-expression of additional specific
genes mapped to this area in cells selected for resistance to
BCNU. This suggests that sequences in this region may be
contributing to a novel mechanism of resistance.
We have recently begun studies of microRNA (miRNA)
expression in cells selected for resistance to BCNU. Pre-
liminary results suggest that hsa-let-7b is over-expressed
in ME cells selected for BCNU resistance and MER cells
before and after selection for BCNU resistance. This
miRNA is mapped to chromosome 22q13.31, the region
we have found to be over-represented in BCNU resistance
cells. Other miRNAs mapped to this region include hsa-
let-7a-3 which is just centromeric to let-7b and hsa-mir-33
which is mapped to 22q13.2. Neither of these miRNAs are
over-expressed in these cells, suggesting that this is not
simply a non-specific results of over-representation. While
the precise function of these miRNAs has not been eluci-
dated, the hsa-let7 family has been implicated in the reg-
ulation of ras [20], and reduced expression of hsa-let7 is
associated with poorer survival in lung cancer [21]. Our
current studies are aimed at the identification of the role,
if any, of sequences mapped to chromosome 22 in BCNU
resistance.
Conclusion
In summary, we have found that cells selected for resist-
ance to BCNU either in vitro or in vivo (recurrent tumor)
have over-representation of a specific region of chromo-
some 22 encompassing 22q12.3–13.32. There are no
genes known to be involved in resistance mapped to
22q12.3–13.32, suggesting the presence of a gene or DNA
sequence involved in a novel mechanism contributing to
the growth of resistant cells. Further studies are underway
to identify a gene(s) or non-coding RNA on chromosome
22 that is involved in chemotherapy resistance.
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